Pagibaximab is a monoclonal antibody that targets the human protein known as CD4, which is primarily expressed on the surface of T lymphocytes. This characteristic makes it significant in immunological research and therapeutic applications, particularly in conditions involving immune modulation. As a monoclonal antibody, Pagibaximab is designed to bind specifically to its target, potentially influencing T cell activation and proliferation. Its structure consists of a variable region that recognizes the CD4 antigen and a constant region that mediates immune responses. Pagibaximab has been investigated for its potential use in treating autoimmune diseases and certain types of cancer, where modulation of the immune response is crucial. The CAS number 595566-61-3 uniquely identifies this compound in chemical databases, facilitating its study and application in various scientific and medical contexts. As with many monoclonal antibodies, its development and use are subject to rigorous clinical testing to ensure safety and efficacy in human subjects.

Pagibaximab

595566-61-3: Pagibaximab is a monoclonal antibody that targets the human protein known as CD4, which is primarily expressed on the surface of T lymphocytes. This characteristic makes it significant in immunological research and therapeutic applications, particularly in conditions involving immune modulation. As a monoclonal antibody, Pagibaximab is designed to bind specifically to its target, potentially influencing T cell activation and proliferation. Its structure consists of a variable region that recognizes the CD4 antigen and a constant region that mediates immune responses. Pagibaximab has been investigated for its potential use in treating autoimmune diseases and certain types of cancer, where modulation of the immune response is crucial. The CAS number 595566-61-3 uniquely identifies this compound in chemical databases, facilitating its study and application in various scientific and medical contexts. As with many monoclonal antibodies, its development and use are subject to rigorous clinical testing to ensure safety and efficacy in human subjects.

<p>Chimeric monoclonal antibody targeting staphylococcal lipoteichoic acid; prevents staphylococcal sepsis in infants</p>

<p>Pagibaximab, a chimeric IgG1, targets lipoteichoic acid to prevent staph sepsis from S. aureus/epidermidis.</p>

CAS 595566-61-3

Pagibaximab

Pagibaximab

Ref: 3D-CLA1193

Pagibaximab

Ref: TM-T76822